Thomas Van Stappen

1.2k total citations
26 papers, 937 citations indexed

About

Thomas Van Stappen is a scholar working on Immunology, Epidemiology and Genetics. According to data from OpenAlex, Thomas Van Stappen has authored 26 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 14 papers in Epidemiology and 14 papers in Genetics. Recurrent topics in Thomas Van Stappen's work include Inflammatory Bowel Disease (14 papers), Microscopic Colitis (12 papers) and Biosimilars and Bioanalytical Methods (12 papers). Thomas Van Stappen is often cited by papers focused on Inflammatory Bowel Disease (14 papers), Microscopic Colitis (12 papers) and Biosimilars and Bioanalytical Methods (12 papers). Thomas Van Stappen collaborates with scholars based in Belgium, Netherlands and United States. Thomas Van Stappen's co-authors include Ann Gils, Séverine Vermeire, Marc Ferrante, Gert Van Assche, Niels Vande Casteele, Jeroen Lammertyn, Els Brouwers, Filip Delport, Dragana Spasić and Sophie Tops and has published in prestigious journals such as Gastroenterology, PLoS ONE and Analytical Chemistry.

In The Last Decade

Thomas Van Stappen

26 papers receiving 934 citations

Peers

Countries citing papers authored by Thomas Van Stappen

Since Specialization

Citations

This map shows the geographic impact of Thomas Van Stappen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Van Stappen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Van Stappen more than expected).

Fields of papers citing papers by Thomas Van Stappen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Van Stappen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Van Stappen. The network helps show where Thomas Van Stappen may publish in the future.

Co-authorship network of co-authors of Thomas Van Stappen

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Van Stappen. A scholar is included among the top collaborators of Thomas Van Stappen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Van Stappen. Thomas Van Stappen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-infliximab antibodies: How to compare old and new data? 2019 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Thomas Van Stappen, Griet Compernolle, Sophie Tops, Ann Gils	8
2	Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing 2018 ·Alimentary Pharmacology & Therapeutics ·Bram Verstockt, (unknown), Sumin Bian, Thomas Van Stappen, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante	57
3	Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial 2017 ·Gut ·Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils	89
4	Clinical Relevance of Detecting Anti-Infliximab Antibodies with a Drug-Tolerant Assay: Post-HOC Analysis of the Taxit Trial 2017 ·Gastroenterology ·Thomas Van Stappen, Niels Vande Casteele, Gert A. Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils	3
5	Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis 2016 ·Thomas Van Stappen, L. Bollen, Niels Vande Casteele, (unknown), Nick Geukens, (unknown), (unknown), (unknown), (unknown), Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils	1
6	Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays 2016 ·Journal of Pharmaceutical and Biomedical Analysis ·Sumin Bian, Thomas Van Stappen, Filip Baert, Griet Compernolle, Els Brouwers, Sophie Tops, Annick de Vries, Theo Rispens, Jeroen Lammertyn, Séverine Vermeire, Ann Gils	28
7	Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis 2016 ·Journal of Crohn s and Colitis ·(unknown), Erwin Dreesen, Thomas Van Stappen, Annick de Vries, Els Brouwers, Gert Van Assche, Séverine Vermeire, Marc Ferrante, Ann Gils	69
8	Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade® 2016 ·The AAPS Journal ·Joseph C. Marini, Jocelyn Sendecki, Freddy Cornillie, John Popp, Shawn C. Black, Marion Blank, Ann Gils, Thomas Van Stappen, Dörte Hamann, Theo Rispens, (unknown), Kelly Chun, Gopi Shankar	43
9	Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation 2016 ·Clinical and Translational Gastroenterology ·Thomas Van Stappen, (unknown), Niels Vande Casteele, Konstantinos Papamichael, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils	47
10	Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples 2016 ·Inflammatory Bowel Diseases ·Ann Gils, Thomas Van Stappen, Erwin Dreesen, (unknown), Séverine Vermeire, Paul Declerck	40
11	Patients with High Anti-drug Antibody Titers Require a Higher Cumulative Infliximab Dose to Achieve Target Drug Concentrations: A Post-hoc Analysis of the TAXIT Trial 2016 ·The American Journal of Gastroenterology ·Niels Vande Casteele, Thomas Van Stappen, Gert Van Assche, (unknown), Séverine Vermeire, Ann Gils	1
12	697 Analytical and Clinical Validation of a Rapid Point-of-Care Assay for Infliximab Quantification in Patients With Ulcerative Colitis 2016 ·Gastroenterology ·Thomas Van Stappen, (unknown), Niels Vande Casteele, (unknown), Nick Geukens, (unknown), (unknown), (unknown), (unknown), Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils	1
13	The biosimilars of infliximab are equally well quantified in a clinically validated infliximab assay 2015 ·Ann Gils, (unknown), Erwin Dreesen, Thomas Van Stappen, Paul Declerck	4
14	Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients 2015 ·Biosensors and Bioelectronics ·(unknown), Thomas Van Stappen, Dragana Spasić, Filip Delport, Séverine Vermeire, Ann Gils, Jeroen Lammertyn	118
15	Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis 2015 ·Clinical Gastroenterology and Hepatology ·Konstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Sophie Tops, Karolien Claes, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Marc Ferrante	127
16	An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases 2015 ·Inflammatory Bowel Diseases ·Thomas Van Stappen, Thomas Billiet, Niels Vande Casteele, Griet Compernolle, Els Brouwers, Séverine Vermeire, Ann Gils	35
17	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases 2015 ·Alimentary Pharmacology & Therapeutics ·(unknown), Thomas Van Stappen, Vipul Jairath, K Gecse, Reena Khanna, Geert D’Haens, Séverine Vermeire, Ann Gils, Brian G. Feagan, Barrett G. Levesque, Niels Vande Casteele	44
18	Multifunctional iron oxide nanoparticles for biomedical applications 2015 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Maarten Bloemen, (unknown), Thomas Van Stappen, Luc De Meester, Nick Geukens, Ann Gils, Thierry Verbiest	1
19	Heterobifunctional PEG Ligands for Bioconjugation Reactions on Iron Oxide Nanoparticles 2014 ·PLoS ONE ·Maarten Bloemen, Thomas Van Stappen, Pieter Willot, Jeroen Lammertyn, Guy Koeckelberghs, Nick Geukens, Ann Gils, Thierry Verbiest	28
20	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays 2014 ·Therapeutic Drug Monitoring ·Thomas Van Stappen, Els Brouwers, Sophie Tops, Nick Geukens, Séverine Vermeire, Paul Declerck, Ann Gils	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact